Related Experiment Video
Updated: Mar 25, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials
Graham C Treasure1, Evgenia Aga, Ronald J Bosch
1*Brigham and Women's Hospital, Harvard Medical School, Boston, MA; †University of North Carolina, Chapel Hill, NC; ‡Harvard T. H. Chan School of Public Health, Boston, MA; §University of Pittsburgh, Pittsburgh, PA; ‖Ohio State University, Columbus, OH; and ¶Massachusetts General Hospital and Ragon Institute, Harvard Medical School, Boston, MA.
Abstract:
Viral load (VL) rebound timing and set point were analyzed in 235 participants undergoing analytic treatment interruption (ATI) in 6 AIDS Clinical Trials Group studies. There was no significant association between rebound timing and ATI VL set point for those who rebounded ≤12 weeks. VL set points were lower in participants with rebound >12 weeks (P < 0.001) and participants treated during early infection (P < 0.001). Pre-antiretroviral therapy VL correlated with set point, though 68% of participants had a set point lower than pre-antiretroviral therapy VL. These results illustrate complex relationships between post-ATI virologic outcomes and the potential presence of biological factors mediating rebound timing and set point.
More Related Videos
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
09:54Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis